APA (7th ed.) Citation

G, H., X, W., Y, S., Y, T., & P, C. (2026). Taletrectinib in ROS1+ non-small cell lung cancer: A cost-effectiveness analysis in the United States. Frontiers in pharmacology, 17, 1684603. https://doi.org/10.3389/fphar.2026.1684603

Chicago Style (17th ed.) Citation

G, Huo, Wang X, Song Y, Tian Y, and Chen P. "Taletrectinib in ROS1+ Non-small Cell Lung Cancer: A Cost-effectiveness Analysis in the United States." Frontiers in Pharmacology 17 (2026): 1684603. https://doi.org/10.3389/fphar.2026.1684603.

MLA (9th ed.) Citation

G, Huo, et al. "Taletrectinib in ROS1+ Non-small Cell Lung Cancer: A Cost-effectiveness Analysis in the United States." Frontiers in Pharmacology, vol. 17, 2026, p. 1684603, https://doi.org/10.3389/fphar.2026.1684603.